Furthermore, stabilization of eNOS protein levels during hypoxia through inhibition of miR-200b’s effects and the corresponding increase in NO release may provide a novel therapeutic opportunity for increasing NO bioavailability during various cardiovascular diseases. Here, NOS3 is linked to cardiovascular disorder.